Relation of Aspirin Resistance to Coronary Flow Reserve in Patients Undergoing Elective Percutaneous Coronary Intervention
| Autor: | Stephen W.L. Lee, Wai-Hong Chen, Hung-Fat Tse, Xi Cheng, Chu-Pak Lau, Pui-Yin Lee, Jeanette Yat-Yin Kwok, William Ng |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
medicine.medical_specialty Ticlopidine medicine.medical_treatment Drug Resistance Coronary Circulation Angioplasty Internal medicine medicine Humans cardiovascular diseases Myocardial infarction Angioplasty Balloon Coronary Aged Aspirin business.industry Percutaneous coronary intervention Coronary flow reserve Thrombolysis Middle Aged Clopidogrel medicine.disease Treatment Outcome Conventional PCI Linear Models Cardiology Female Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | The American Journal of Cardiology. 96:760-763 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/j.amjcard.2005.04.056 |
| Popis: | Previous studies have shown that more complete platelet inhibition improves the coronary flow reserve (CFR), a measure of microvascular integrity, in patients undergoing percutaneous coronary intervention (PCI). We hypothesized that patients with aspirin resistance would have impaired CFR after elective PCI. We used VerifyNow Aspirin to determine the response to aspirin in 117 consecutive patients who underwent elective single-lesion PCI. The assay results are expressed quantitatively in Aspirin Reaction Units based on the degree of platelet aggregation. All patients received a 300-mg loading dose of clopidogrel >12 hours before and a 75-mg maintenance dose the morning of PCI. CFR was estimated using the Thrombolysis In Myocardial Infarction frame count method. Of the 117 patients, 22 (18.8%) were aspirin resistant. The clinical, angiographic, and procedural characteristics of the aspirin-sensitive and -resistant patients were balanced. All patients underwent successful PCI with |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect